Mind Medicine (MindMed) Inc.

NASDAQ•MNMD

CEO: Mr. Robert Barrow

セクター: Healthcare

業種: Biotechnology

上場日: 2016-11-15

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

連絡先情報

One World Trade Center, Suite 8500, New York, NY, 10007, United States

212-220-6633

www.mindmed.co

時価総額

$1.36B

PER (TTM)

-8.8

17.9

配当利回り

52週高値

$19.62

52週安値

$4.70

52週レンジ

89%

順位68Top 98.2%

1.3

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.51+0.00%

直近4四半期の推移

フリーCF

-$72.54M+0.00%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

October Offering Secures Funding Raised $242.8M net proceeds in October 2025 offering, extending cash runway into 2028 based on current plans.

R&D Spending Ramps Up Nine-month R&D expenses hit $84.1M USD, surging 93% compared to $43.5M USD in the prior year period.

MM120 Phase 3 Trials Underway Phase 3 GAD trials Voyage/Panorama anticipate topline readouts in H1/H2 2026, advancing key lead candidate.

Current Cash Position Cash, equivalents, and investments totaled $209.1M USD as of September 30, 2025, supporting near-term operations.

リスク要因

Net Loss Widens Substantially Nine-month net loss reached $(133.4)M USD, significantly worse than the $(73.9)M USD reported in the prior year.

Continued Need for Capital Operations require substantial future funding; current cash runway extends only into 2028 based on projections without further financing.

Warrant Liability Volatility Change in fair value of 2022 Warrants caused $(17.8)M USD expense in the nine-month period due to share price movement.

Clinical Trial Execution Risk Success hinges on pivotal Phase 3 trials for MM120 in GAD and MDD, facing ongoing regulatory review and design changes.

見通し

MM402 Phase 2a Initiation Plan to initiate Phase 2a open-label trial for MM402 targeting ASD in the fourth quarter of 2025 with up to 20 participants.

MM120 MDD Phase 3 Planning Anticipate initiating a second Phase 3 trial, Ascend (MM120-311), for Major Depressive Disorder indication in mid-2026.

G&A Expenses Projected Rise Expect general and administrative costs to increase for the foreseeable future as the business grows and prepares for commercialization.

Exploring New Indications Continue exploring additional programs and potential new indications for lead product candidates through external collaborations.

同業比較

売上高 (TTM)

ANAB

$234.60M

+157.0%

XNCR

$125.58M

+4.0%

URGN

$85.57M

-5.3%

粗利益率 (最新四半期)

ANAB

199.8%

+99.5pp

URGN

91.3%

-2.2pp

XNCR

90.9%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
TNGX	$2.01B	-19.8	-50.3%	8.4%
ANAB	$1.86B	-136.1	1813.8%	79.8%
NKTR	$1.49B	-9.1	-484.9%	0.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月6日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし